+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Analysis: Xolair

  • PDF Icon

    Drug Pipelines

  • 19 Pages
  • February 2018
  • Region: Global
  • Citeline
  • ID: 4489116
Drug Overview

Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.

Table of Contents

1 Product Profiles
  • Xolair: Asthma

List of Figures
Figure 1: Asthma - current and future market dynamics analysis
Figure 2: The author’s drug assessment summary of Xolair in asthma
Figure 2: The author’s assessment summary of key marketed and pipeline drugs for asthma
Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Xolair drug profile
Table 2: Xolair pivotal trial data in asthma
Table 3: Xolair late-phase trial data in asthma
Table 4: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Companies Mentioned

  • Roche
  • Novartis